Upexi Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

UpexiDie Umsatzerlöse des Unternehmens werden voraussichtlich um 13.5% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 71% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 76.1% pro Jahr wachsen.

Wichtige Informationen

71.0%

Wachstumsrate der Gewinne

76.1%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	26.2%
Wachstumsrate der Einnahmen	-13.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:UPXI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2025	70	-7	N/A	N/A	1
6/30/2024	79	-10	N/A	N/A	1
3/31/2024	84	-23	-6	-5	N/A
12/31/2023	91	-20	-7	-6	N/A
9/30/2023	97	-14	-1	0	N/A
6/30/2023	81	-15	-1	0	N/A
3/31/2023	66	-2	0	0	N/A
12/31/2022	49	-1	1	2	N/A
9/30/2022	30	-7	-9	-4	N/A
6/30/2022	23	-6	-6	0	N/A
3/31/2022	24	-1	-2	5	N/A
12/31/2021	26	0	-1	5	N/A
9/30/2021	25	3	3	4	N/A
6/30/2021	24	3	2	3	N/A
3/31/2021	16	0	0	0	N/A
12/31/2020	11	-3	-2	-2	N/A
9/30/2020	9	-5	-4	-3	N/A
6/30/2020	7	-5	-6	-4	N/A
6/30/2019	2	-1	-1	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: UPXI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: UPXI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: UPXI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: UPXIDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-13.5% pro Jahr).

Hohe Wachstumseinnahmen: UPXIDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-13.5% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von UPXI in 3 Jahren voraussichtlich hoch sein wird

Upexi Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Recent updates

Upexi Receives Notice from the Nasdaq Stock Market

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024

Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price Requirement

Upexi, Inc. announced delayed annual 10-K filing

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken